| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5912728 | Multiple Sclerosis and Related Disorders | 2013 | 11 Pages |
Abstract
⺠4-AP shows clinical utility in treating walking disability in MS. ⺠KV1 and KV3 voltage-gated K+ channel sub-types, expressed in axons, are blocked by 4-AP. ⺠4-AP targets K+ channels on the basis of channel molecular structure and membrane potential. ⺠Pre-synapse activation probability is increased by systemic 4-AP.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Mark D. Baker,